A research endeavor that seeks to develop a new cancer immunotherapy utilizing nanobody delivery and targeted heating of tumors has received funding from the Waddell Walker Hancock Cancer Discovery Fund. John Wilson, PhD, and Jeffrey Rathmell, PhD, aim to create a novel therapeutic that will reprogram regulatory T cells, which typically suppress immune responses, into killer T cells with antitumor activity. The key to this reprogramming is the STING signaling pathway, and the force needed to unlock it is fever-relevant temperature — a hypothesis based on recent discoveries from the group on how fevers affect immune responses.